Literatur
- 1
Adams J.
The proteasome: structure, function, and role in the cell.
Cancer Treat Rev.
2003;
29
(Suppl 1)
3-9
- 2
Albanell J, Adams J.
Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic.
Drugs of the Future.
2002;
27
1079-1092
- 3
Rajkumar S V, Richardson P G, Hideshima T, Anderson K C.
Proteasome inhibition as a novel therapeutic target in human cancer.
J Clin Oncol.
2005;
23
630-639
- 4
Pekol T, Daniels J S, Labutti J. et al .
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating
metabolites.
Drug Metab Dispos.
2005;
33
771-777
- 5
Dubey S, Schiller J H.
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
Oncologist.
2005;
10
282-291
- 6 EMEA .Velcade-EMEA-H-539-00-00-PI - Zusammenfassung der Merkmale des Arzneimittels. 4/2004:
1-34
- 7
Ghobrial I M, Witzig T E, Adjei A A.
Targeting apoptosis pathways in cancer therapy.
CA Cancer J Clin.
2005;
55
178-194
- 8
Schwartz R, Davidson T.
Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Oncology (Williston Park).
2004;
18
14-21
- 9
Papandreou C N, Daliani D D, Nix D. et al .
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid
tumors with observations in androgen-independent prostate cancer.
J Clin Oncol.
2004;
22
2108-2121
- 10 EMEA .EPAR Velcade - Scientific Discussion. 2004: 1-42
- 11
Richardson P G, Barlogie B, Berenson J. et al .
A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med.
2003;
348
2609-2617
- 12
Richardson P G, Sonneveld P, Schuster M W. et al .
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med.
2005;
352
2487-2498
- 13 National Cancer Institute BM .Common Toxicity Criteria. Version 2.0 (NCI-CTC Version
2.0). 4/1999
- 14 Janssen-Cilag International NV .Fachinformation Velcade®. 4/2005
- 15
Dy G K, Thomas J P, Wilding G. et al .
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341
(bortezomib, velcade), in patients with advanced cancer.
Clin Cancer Res.
2005;
11
3410-3416
- 16
Giaccone G.
Clinical potential of proteasome inhibition in solid tumors.
EJC Suppl.
2004;
2
25-28
- 17
Lenz H J.
Clinical update: proteasome inhibitors in solid tumors.
Cancer Treat Rev.
2003;
29
(Suppl 1)
41-48
- 18
Cortes J, Thomas D, Koller C. et al .
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clin Cancer Res.
2004;
10
3371-3376
- 19
O’Connor O A, Wright J, Moskowitz C. et al .
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients
with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma.
J Clin Oncol.
2005;
23
676-684
- 20
Goy A, Younes A, McLaughlin P. et al .
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell
non-Hodgkin’s lymphoma.
J Clin Oncol.
2005;
23
667-675
- 21
Stevenson J, Nho C W, Schick J, Johnson S W, Algazy K, Miller D.
Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced
non-small cell lung cancer.
Am Soc Clin Oncol.
2003;
22
202
- 22
Davis N B, Taber D A, Ansari R H, Ryan C W, Vokes E E, Vogelzang N J.
A phase II trial of PS-341 in patients with renal cell cancer.
Proc Am Soc Clin Oncol.
2003;
22
386
- 23
Drucker B J, Schwartz L, Bacik J, Mazumdar M, Marion S, Motzer R J.
Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma.
Proc Am Soc Clin Oncol.
2005;
22
386
- 24
Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M.
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib
in patients with metastatic colorectal cancer.
Clin Cancer Res.
2005;
11
5526-5533
- 25
Shah M H, Young D, Kindler H L, Webb I, Kleiber B, Wright J.
Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic
Neuroendocrine Tumors.
Clin Cancer Res.
2004;
10
6111-6118
- 26
Markovic S N, Geyer S M, Dawkins F. et al .
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Cancer.
2005;
103
2584-2589
Prof. Dr. Ulrich Jaehde
Pharmazeutisches Institut, Universität Bonn
An der Immenburg 4
53121 Bonn
